NOV 03, 2015 08:00 AM PST
WEBINAR: Health economic value of calprotectin testing: A gastroenterologist's perspective
SPONSORED BY: Inova Diagnostics
13 29 7689

Speakers:
  • Assistant Professor of Pediatrics (Gastroenterology), Lucile Salter Packard Children's Hospital, Stanford School of Medicine
    Biography
      I am an Assistant Professor in the Division of Gastroenterology, Department of Pediatrics, and a Stanford Health Policy faculty associate. I serve as the Co-Director of Stanford Children's IBD Center and the medical director of the Short Stay Infusion Unit at Stanford Children's Health. My scientific investigation stems from my formal training in health services/policy research with background in biostatistics, study design, database analysis, and decision science. My current NIH-funded research is to discover cost-effective ways to manage Crohn's disease and ulcerative colitis. Recently, my work has focused on two clinical pathways to improve value of care: best use of expensive but effective biological therapies and optimal ways to monitor intestinal inflammation using a non-invasive stool biomarker in fecal calprotectin. Calprotectin is a protein that is extruded when there is cell death of intestinal neutrophils and macrophages, reliably detecting inflammation in the gastrointestinal tract. With a team of investigators representing both breadth and depth of different expertise - including sub-fields in medicine, business, psychology, management science, engineering, economics, and industry - we seek to apply existing large data with clinician observations in patient care to translate quality-improvement ideas into hypothesis-tested and easily-implementable care strategies in the management of chronic gastrointestinal diseases, particularly those with child health significance. I was born in Seoul, South Korea and grew up in Chattanooga, Tennessee. I received my BA in chemistry and biochemistry at Duke University, MD from The University of Tennessee, and MS in Health Policy Research at Stanford University, where I also completed my subspecialty clinical training in gastroenterology, hepatology, and nutrition.

    Abstract:

    FREE to register and attend!

    •    Patients presenting with persistent abdominal pain and diarrhea are common in clinical practice. Evaluation of these patients, assuming no alarm symptoms, can be difficult.  Inflammatory bowel disease is always a possibility and while few will actually have IBD, the symptoms of IBS and IBD can overlap.   Concern with a missed diagnosis of IBD leads many clinicians to request endoscopic evaluation.  

    •    Most endoscopies are negative with over half of endoscopies on individuals with non-bleeding symptoms being diagnosed with non-organic disease, usually IBS.1   Up to 70% of children and teenagers referred to a pediatric gastroenterology center for suspected IBD did not have the disease.2  Furthermore, although endoscopic procedures are relatively common, they are invasive, costly, require patient compliance with fasting and bowel preparation, involve sedation, are subjective.  

    •    The strategy of testing for fecal calprotectin, a calcium and zinc binding protein complex found in neutrophil cytosolic protein,  utilizes non-invasive diagnostic testing to stratify patients in need of endoscopic confirmation, reducing costs and improving the overall patient healthcare experience

     

    1. Yang Z, Clark N, and Park KT. Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children. Clin Gastroenterol Hepatol 2014; 12(2): 253-262.
    2. Van de Vijver E, Schreuder A, Cnossen W, Muller K, and van Rheenen P and the North Netherlands Pediatric IBD Consortium. Safely ruling out inflammatory bowel disease in children and teenagers without referral for endoscopy. Arch Dis Child 97:1014-1018.


    Show Resources
    Loading Comments...